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Allosteric interactionUnderstanding the communication pathways between remote sites in proteins is of key importance for under-
standing their function and mechanism of action. These remain largely unexplored among the pleiotropic drug
resistance (PDR) representatives of the ubiquitous superfamily of ATP-binding cassette (ABC) transporters. To
identify functionally coupled residues important for the polyspeciﬁc transport by the fungal ABC multidrug
transporter Cdr1p a new selection strategy, towards increased resistance to a preferred substrate of the homol-
ogous Snq2p, was applied to a library of randomly generatedmutants. The single amino acid substitutions, locat-
ed pseudosymmetrically in each domain of the internally duplicated protein: the H-loop of the N-terminal
nucleotide binding domain (NBD1) (C363R) and in the C-terminal NBD2 region preceding Walker A (V885G).
The central regions of the ﬁrst transmembrane helices 1 and 7 of both transmembrane domainswere also affect-
ed by the G521S/D and A1208V substitutions respectively. Although the mutants were expressed at a similar
level and located correctly to the plasmamembrane, they selectively affected transport of multiple drugs, includ-
ing azole antifungals. The synergistic effects of combined mutations on drug resistance, drug dependent ATPase
activity and transport support the view inferred from the statistical coupling analysis (SCA) of aminoacid coevo-
lution and mutational analysis of other ABC transporter families that these residues are an important part of the
conserved, allosterically coupled interdomain communication network. Our results shed new light on the com-
munication between the pseudosymmetrically arranged domains in a fungal PDR ABC transporter and reveal its
profound inﬂuence on substrate speciﬁcity.
© 2012 Elsevier B.V. All rights reserved.1. Introduction
ABC transporters constitute a major and ubiquitous protein super-
family controlling the membrane translocation of a large number of
structurally diverse solutes ranging from low molecular weight mole-
cules to large polymers including proteins [1]. Many prokaryotic and
eukaryotic ABC transporters are involved in the control of membrane
permeation to compounds used in the chemotherapy of bacterial and
fungal infections and cancer [2–4]. Overproduction of the polyspeciﬁc
multidrug resistance (MDR) ABC transporters is the prevailing mecha-
nism of resistance to antifungals.
Cdr1p is the major MDR ABC transporter conferring resistance to
azoles and other structurally unrelated compounds in themost frequentiotropic drug resistance; ABC,
TMD, transmembrane domain;
NQO, 4-nitroquinoline 1-oxide;
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rights reserved.human fungal pathogen Candida albicans [5]. In the related model yeast
Saccharomyces cerevisiae a similar role is played by the homologous
Pdr5p, which shows an overlapping yet distinct speciﬁcity with the
closely related Snq2p [6].
These transporters are representatives of the Pleiotropic Drug Resis-
tance (PDR) subfamily of ABC transporters classiﬁed to two different
clusters A (Cdr1, Pdr5p) and D (Snq2p) based on recent phylogenetic
analyses [7,8]. Interestingly PDR subfamily members are unique to
fungi and plants [9–13]. Their characteristic feature, in contrast to
other ABC superfamily members including mammalian P-glycoproteins
involved in cancer cell chemotherapy resistance, is the inverted topolo-
gy. The minimal functional unit believed to operate in most ABC trans-
porters is a symmetrically arranged tandem repeat of the nucleotide
binding (NBD) and transmembrane domains (TMD): TMD1–NBD1–
TMD2–NBD2, which in the PDR subfamily shows themirror image orga-
nization: NBD1–TMD1–NBD2–TMD2 [14–16].
The observed two-foldmolecular symmetry of domain arrangement,
resulting from the internal duplication is implied, according to the alter-
nating access model, to have important consequences for the mecha-
nism of drug transport and harnessing energy from ATP-hydrolysis. Its
mutational analysis by a rational approach is hindered by the scarce
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porters is limited to low resolution single particle analysis of Pdr5p [17],
as well as the usually observed large sequence divergence of the dupli-
cated subunits.
In the PDR-subfamily these are encoded as a single polypeptide, in
which even the consensus regions of C-loop, Walker A and the H-loop
of the two NBDs contain substitutions of the critical and highly con-
served amino acid residues [7,8] and are not interchangeable [18].
Such degeneracy is not limited to the PDR subfamily. It has also
been observed in other ABC proteins, such as the human Tap complex
involved in the presentation of antigenic peptides in the immune
system, the CFTR chloride channel whose defects lead to cystic ﬁbro-
sis, the multidrug resistance associated protein MRP1 and the subunit
of the ATP-sensitive potassium channel regulating insulin release SUR1,
suggesting a functional nonequivalence of the two NBDs [19–23]. In
CFTR a prolonged binding of ATP occurs at the NBD1 site, whereas its
rapid turnover and hydrolysis at the NBD2 site is coupled to chloride
channel gating [20]. Based on this functional nonequivalence, reﬂected
by a large sequence divergence, possible mechanistic differences with
transporters having the critical regions conserved in both halves, such
as P-glycoprotein have been postulated [21,24]. In P-glycoprotein ATP
hydrolysis at both NBDs occurring in an alternating fashion was re-
quired for drug transport [25,26] and even the complete substitution
of the C-terminal NBD by the N terminal one resulted in a transport ca-
pable chimera [27].
Intriguingly however, despite the structural differences the repre-
sentatives of the fungal-type PDR subfamily of ABC transporters Pdr5p
and Cdr1p, sharewithmammalian P-glycoproteinsmany common sub-
strates and inhibitors implying some functional and mechanistic simi-
larities. Crucial for their understanding is uncovering of the functional
coupling between selected residues important for the long distance
interdomain allosteric interactions. These, shown to operate in other
protein families and to impact their substrate speciﬁcity [28–31], are
poorly understood in the members of the ubiquitous ABC superfamily.
A light on these complex interdomain interactions has been shed by
the recent analysis of the S. cerevisiae Pdr5p mutants, which revealed
communication between transmembrane helix 2 and the Q loop region
of NBD1 with the involvement of intracellular loop 1 [32,33].
Our results build on the previous extensive characterization of drug
speciﬁcity proﬁles of yeast PDR transporters [6,34]. This allowed for the
design of a new in vivo selection procedure of randomly generated
Cdr1p gain of function mutants, that conferred increased level of re-
sistance towards speciﬁc substrates of the homologous Snq2p. Interest-
ingly the analysis reveals a pseudosymmetrical location of residues
involved in communication between substrate and nucleotide binding
domains and selectively affecting transport speciﬁcity.
2. Materials and methods
2.1. Strains and media
The following yeast strains were used in this study: AK100 (MATa,
ura3-52, trp1Δ63, leu2Δ1, his3Δ200, GAL2+, PDR1–3, pdr5-Δ4::
rep500, snq2-Δ1::hisG, yor1-1::hisG), MKCDR1h (MATa, ura3–52,
trp1Δ63, leu2Δ1, his3Δ200, GAL2+, PDR1–3, pdr5-Δ4::CDR1h,
snq2-Δ1::hisG, yor1-1::hisG), MKSNQ2h (MATa, ura3–52, trp1Δ63,
leu2Δ1, his3Δ200, GAL2+, PDR1–3, pdr5-Δ4::SNQ2h, snq2-Δ1::
hisG, yor1-1::hisG) [34], cells were grown on rich YPD or on synthetic
complete medium lacking the relevant auxotrophic components.
2.2. Random mutagenesis, selection, subcloning and chromosomal
integration of the mutant alleles
The pMKCDR1h plasmid [34] was treated with hydroxylamine as
described previously [35]. After transformation into AK100, cells were
plated on resazurine containing synthetic complete medium lackinguracil, supplemented with 2% glycerol and 2% ethanol. The drug resis-
tance phenotypes of mutant plasmids were veriﬁed after isolation
from streak-puriﬁed colonies and retransformation into AK100. The
sequence of the resulting clones bearing single point mutations was
determined by the Sanger dideoxy chain termination procedure [36].
Combined mutations were generated by subcloning of the corre-
sponding fragments with restriction endonucleases, using standard
procedures. The presence of mutations, resulting either in the loss
or gain of an additional restriction endonuclease site, was conﬁrmed
by agarose gel electrophoresis after digestion of the whole plasmid
or its PCR-ampliﬁed fragments.
The chromosomal integration of mutant alleles, was achieved by
transformation of the isolated linear fragments, containing the entire
CDR1 open reading frame ﬂanked by the promoter and terminator re-
gions of PDR5, into the AK100 strain, essentially as previously described
[34]. The resulting clones were veriﬁed by colony PCR and sequencing.
Susceptibility of yeast to growth inhibition was determined as
previously described [34]. At least four independently isolated clones
were compared in the growth assays of drug resistance. The drug re-
sistance proﬁles of the representative integrants were in agreement
with those obtained with plasmid transformants.
2.3. Plasma membrane isolation
Isolation of plasma membranes was performed according to the
glass-bead lysis procedure [37], with minor modiﬁcations [38]. Mem-
branes were analyzed by sodium dodecyl sulfate (SDS)-polyacrylamide
gel electrophoresis and stained with Coomassie brilliant blue R-250
(Bio Rad).
2.4. Immunological methods
Protein extracts were prepared and the protein concentration was
determined as previously described [39]. After separation of equal
protein amounts by SDS-PAGE and transfer, blots were incubated
with India HisProbe-HRP (Pierce) and anti-Vph1p antibody (Molecular
Probes). Blots were developedwith the SuperSignalWest Pico chemilu-
minescent substrate (Pierce).
2.5. Transport and ATPase activity measurements
The accumulation of resoruﬁn acetate (Fluka) was measured under
similar conditions to those described previously [34]. Brieﬂy, the reac-
tion was started by addition of resoruﬁn acetate to energized cells col-
lected during the exponential phase of growth. Fluorescence intensity
was recorded with a Molecular Devices Gemini EMmicroplate spectro-
ﬂuorometer at 544 nm excitation and 590 nm emission wavelengths.
Measurements of ATPase activity were performed essentially as
previously described [37], with minor modiﬁcations. Brieﬂy, plasma
membranes were suspended in 100 mMbuffer of desired pH. The reac-
tions were started by addition of MgCl2 and ATP and carried at 30 °C.
After termination at multiple time points, to assure linearity, the con-
centration of liberated inorganic phosphate was determined as de-
scribed previously [37]. To optimize conditions, the ATPase pH proﬁles
were determined in Mes-NaOH (pH 5.5; 6; 6.5), Mops-NaOH (pH 6.5;
7), Hepes-NaOH (pH 7; 7.5; 8), Taps-NaOH (pH 8; 8.5; 9) in the pres-
ence or absence of several metabolic inhibitors including oligomycin
(12.5 μg/ml ) (inhibitor of Cdr1p and the mitochondrial ATPase), vana-
date (50 μM) (inhibitor of Cdr1p and Pma1p) sodium azide (12.5 mM)
(inhibitor of mitochondrial ATPase), nitrate (50 mM) (inhibitor of vac-
uolar ATPase) and ammonium molybdate (200 μM) (inhibitor of non-
speciﬁc phosphatases). Membranes from the expression host not
containing Cdr1p were used as an additional negative control. The van-
adate sensitive, oligomycin insensitive Pma1p activity was used as a
positive control to monitor the quality of membrane preparations. The
pH ranges of buffers overlapped to monitor possible indirect effects of
Fig. 1. Pseudosymmetrical localization of mutations involved in the switch of Cdr1p sub-
strate speciﬁcity towards compounds preferred by Snq2p along the two fold rotational
symmetry axis observed in ABC transporters. A) Schematic representation of the primary
Cdr1p structure revealing that eachof the internally duplicateddomains is affected. B) The
detailed location of theC363R in theH loop ofNBD1, forming the degenerate ATP compos-
ite site 1. The V885G lies in the region preceding Walker A of NBD2 in the canonical ATP
composite site 2. C) Localization of the corresponding residues L536 and I364 in the nucle-
otide binding domains of Sav1866 based on structure basedmultiple sequence alignment
and the available atomic coordinates of this homodimer composed of the duplicated
TM-NBD subunits of identical primary structure (2HYD). The top view from the TM do-
main side (removed for clarity) on the dimer of both NBD subunits characterized by a
twofold rotational symmetry reﬂecting the perfect symmetry of the primary structure.
The image was generated with UCSF Chimera [51].
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served, the effects of Cdr1p drug substrates were routinely performed
in 100 mM Hepes pH 7.5, supplemented with 12.5 mM sodium azide
at saturating Mg-ATP concentrations (8 mM).
DiOC6 transport in isolated plasma membranes was measured
under similar conditions to those described previously for rhodamine
6 G transport by Pdr5p [34,38] with minor modiﬁcations: the reac-
tion buffer contained 100 mM Hepes pH 7.5 and 12.5 mM sodium
azide, excitation and emission wavelengths were 485 nm and 510, re-
spectively. Reactions were started by addition of MgCl2 and ATP
(8 mM ﬁnal concentration unless indicated differently) and carried
at 30 °C.
2.6. Computational analysis of amino acid coevolution and structural
visualization
The statistical coupling analysis (SCA) [40] was performed, with the
help of the integrated system for residue coevolution [41]. The analysis
of the calculated coevolution perturbation matrix was performed using
the previously implemented [42], two dimensional, coupled two way
clustering procedure [43,44]. Data were visualized with the help of
Java Treeview [45] and MeV [46].
The inputmultiple alignmentwas generated withMUSCLE [47] on a
large representative set of 600 homologous sequences retrieved from
the BLAST search of the available non-redundant protein sequences.
An Expresso (3D-Coffee) multiple sequence alignment (MSA) [48]
was performed based on the structures of NBD domains of ABC proteins
available from the Protein Data Bank. The prediction of secondary struc-
turewas performed by PORTER [49] and that of transmembrane helices
by the SPLIT 4.0 server [50].
Molecular graphics images were produced using the UCSF Chimera
package from the Resource for Biocomputing, Visualization, and Infor-
matics at the University of California, San Francisco (supported by NIH
P41 RR001081) [51].
3. Results
3.1. Pseudosymmetrical distribution of Cdr1p residues important
for substrate speciﬁcity
To identify residues of Cdr1p important for substrate speciﬁcity
we took a new approach aiming at the alteration of its resistance pro-
ﬁle towards previously identiﬁed compounds speciﬁcally detoxiﬁed
by the homologous Snq2p [6]. Saccharomyces cerevisiaemutants of in-
creased resistance to resazurine were selected from a pool of approx-
imately 400 000 transformants, containing the library of mutagenized
Cdr1p expression plasmid. Thirty-ﬁve resistant clones were initially
isolated, from which the plasmids were rescued and retransformed
into the expression host. The 10 clones remaining after conﬁrmation
of plasmid-borne phenotypes and initial characterization of the alter-
ations in the drug resistance proﬁles were sequenced. This revealed
the presence of ﬁve single base substitutions in the CDR1 open read-
ing frame. These resulted in single amino acid substitutions, some oc-
curring in multiple clones, which were pseudosymmetrically located
in each domain of the internally duplicated Cdr1p primary structure.
The mutations found at the beginning of both TMDs were placed in
the corresponding central regions of TM helices 1 and 7 (Fig. 1 A.).
Guanine 1561 in the nucleotide sequence was substituted twice by
A and G1562 once by A, leading to the exchange of Gly 521 by larger
and more polar S or D respectively, located in the central part of TM
helix 1, encompassing residues 514–535 of the N-terminal TMD1.
The corresponding region of the C-terminal TMD2 was affected in four
clones containing the C3623T substitution, leading to the replacement
of Ala 1208 by the larger andmore hydrophobic Val in the central region
of the TM helix 7, encompassing residues 1197–1214 (Fig. 1A).Two additional substitutions were located in the NBDs which, in
contrast to the TM regions, show high degree of primary structure
conservation among ABC transporters. The NBDs form a close contact
upon binding of ATP molecules which are sandwiched between the
Walker A and B motives and the H-loop of the catalytic domain of one
NBD, and the C-loop of the helical signaling domain of the second
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intracellular loops connecting the TM helices. In this way two con-
formationally coupled composite ATP-binding sites are formed with
the contribution of the conserved regions of bothNBDs (Fig. 1B) [52,53].
Interestingly the identiﬁed mutations of Cdr1p NBDs, inﬂuencing
substrate speciﬁcity, affected both ATP composite sites I and II. One of
them, resulting from the T2654G base substitution, leads to the ex-
change of Val 885 into Gly at the 10th position upstream of the Walker
A region of NBD2 within the canonical ATP composite site II (Fig. 2A).
In the two remaining clones with the T1087C base substitutions, theFig. 2. Location of the identiﬁed mutations with the help of structure based Expresso
(3D-Coffee) multiple sequence alignment of the NBD domains of fungal ABC transporters
of the PDR subfamily with NBD domains of other ABC proteins of known 3D structure.
A) Thealigning region aroundWalker Amotif of selected proteins is shown. The substituted
V885 residue of Candida albicans Cdr1p NBD2 is marked by a star. B) The H-loop region of
the degenerate N-terminal NBD1 affected by the C363R substitution (indicated by the star)
and the canonical C-terminal NBD2 of selected fungal PDR ABC transporters (with the con-
served histidine indicated by H) is shown.corresponding Cys 363 was replaced by the much larger R in the degen-
erate H-loop region of NBD1. This is the second position downstream of
the site usually occupied by the conserved histidine in the majority of
ABC transporters, which in the PDR subfamily members has been re-
placed by Y [7,8] (Fig. 2B).
Given the lack of available crystal structures of Cdr1p and other
members of the PDR subfamily, the prediction of the relative location
of the identiﬁed NBD residues was based on a structure based align-
ment of the affected regions of Cdr1p and other fungal transporters
with the sequences of the crystallized NBD domains deposited in the
Protein Data Bank. No gaps were found between the two mutation
sites and the conserved Walker A and H-loop motives respectively
(Fig. 2A and B), which allowed to map precisely the relative locations
of the corresponding residues in NBD domains of known three dimen-
sional structure. A large distance exceeding 30 angstroms separating
residues L536 and I364 of the Sav1866 homodimer in the closed con-
formation, corresponding to C363 and V885 of Cdr1p, respectively is
highlighted in Fig. 1C.
3.2. High level expression of the mutant and wild type Cdr1 alleles
The observed separation of the identiﬁed Cdr1pmutations and their
common effect on substrates of Snq2p raised the possibility of their syn-
ergistic interactions resulting from long distance communication. To
verify this, the single and newly generated multiple mutants were sta-
bly overproduced after integration into the chromosome at the PDR5
locus. The expression level of mutant Cdr1p alleles was comparable to
that of wild type as revealed by Western blot of whole cell extracts
(Fig. 3A). The high and comparable amount of correctly localized mu-
tant and wild type Cdr1p proteins was found in the plasma membrane
fractions as revealed by SDS PAGE analysis of the isolated fractions
(Fig. 3B).
3.3. Changes in drug resistance and transport indicate functional
coupling of the identiﬁed residues involved in substrate speciﬁcity
Analysis of the drug resistance proﬁles revealed selective changes
associatedwith the identiﬁed Cdr1pmutations. As expected, all the sin-
gle mutants showed an increase in resistance to resazurine (Fig. 4A).Fig. 3. Expression level of the overproduced Cdr1 wild type and single and multiple
mutant alleles. A) Western Blot of whole cell extracts. B) Coomasie stained SDS PAGE
of isolated plasma membranes. The positions of the Cdr1p band is indicated. Vph1p
band serving as a loading control is visualized. The position of the marker enzyme of
the yeast plasma membrane Pma1p is indicated. The extracts of the quadruple mutant
C363R, G521S, V885G, A1208V (R+S+G+V) and the expression host bearing the triple
deletion in PDR5, SNQ2 and YOR1 (ΔΔΔ) are indicated.
Fig. 4. Altered drug resistance proﬁles of the single and multiple Cdr1p mutants. Serial
dilutions of indicated drugs in liquid growth medium (supplemented either with
glycerol and ethanol for resazurine and resoruﬁne or glucose for cycloheximide)
were prepared in microtiter plates. Growth was monitored by optical density measure-
ments and visual inspection. The mean values of at least three independent experi-
ments are presented. Error bars have been omitted for clarity.
Fig. 5. Transport of resoruﬁn acetate by wild type Cdr1p and themutants. The increase in
ﬂuorescence intensity is proportional to the level of intracellular accumulation of the
proﬂuorochrome and the release of free resoruﬁn by nonspeciﬁc esterases. A decrease in
the reaction rate indicates increased extrusion by the mutants. The signal from the
Snq2p overproducing strain,which is similar to the cell free buffer control is also indicated.
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similar speciﬁc Snq2p substrate resoruﬁne was observed, as compared
to wild type Cdr1p, which conferred only low level-resistance to bothcompounds (Fig. 4B). To verify that the associated changes in resistance
correspond to the increased transport activity of Cdr1p mutants, a new
ﬂuorescence based assay was developed with the proﬂuorochrome
resoruﬁn acetate as the substrate. A rapid intracellular accumulation
of this compound associated with the release of resoruﬁn ﬂuorescence,
by the activity of nonspeciﬁc cytosolic esterases, was observed in the
case of the expression host strain, in which the genes encoding the
major MDR transporters PDR5, SNQ2 and YOR1 have been deleted
(Fig. 5).
Overproduction of Snq2p completely blocked resoruﬁn acetate
accumulation, and in this case the ﬂuorescence trace was similar to
the cell free buffer control. Although the decrease of resoruﬁn acetate
accumulation observed upon Cdr1p overproduction was much smaller
than in the case of Snq2p, a marked decrease was observed in the mu-
tants (Fig. 5). This was in line with the results of the growth assay, indi-
cating that the mutants are more effective in the extrusion of resoruﬁn
acetate as compared to the wild type Cdr1p. No differences in the rates
of ﬂuorescence increase were observed upon contact of resoruﬁn ace-
tate with glass bead-generated extracts of the analyzed strains, which
conﬁrmed that the differences observed with whole cells result from
alterations of permeation due to changes in active extrusion.
Analysis of the drug related phenotypes of the double Cdr1p mu-
tants to Snq2p-speciﬁc substrates revealed an even higher increase
in resazurine resistance, speciﬁcally resulting from the combination
of G521S and A1208V substitutions (Fig. 4A), indicating the functional
coupling of both TMD residues. This double mutant exerted also an
increased resistance to another Snq2p substrate 4-NQO (not shown).
In contrast, the combined NBDmutations C363R and V885G conferred
the same level of resazurine resistance as the corresponding single
mutants (omitted for clarity in Fig. 4). The same was observed on
resoruﬁne where also the double V885G, A1208V mutant showed
the highest increase in resistance, similar to that exhibited by the
G521S, A1208V combination. An intermediate increase in resistance to
resazurine was observed for the V885G, A1208V as well as the C363R,
G521S double mutants as compared to single substitutions (omitted
for clarity in Fig. 4). The quadruple C363R, G521S, V885G and A1208V
mutation abolished the stimulatory effect of the analyzed single and
double mutants, diminishing the resoruﬁne (Fig. 4B) and resazurine
(omitted for clarity in Fig. 4) resistance to the low level observed with
wild type Cdr1p.
In contrast to Snq2p-speciﬁc substrates, no further increase in
resistance to cycloheximide, which is a preferred substrate of Pdr5p
and Cdr1p, was observed in double mutants, although all single ones
showed a slight increase (Fig. 4C). Importantly the C363R, G521S,
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confer cycloheximide tolerance (Fig. 4C).
3.4. Combined mutations lead to strong synergistic effects on selected
azole antifungals
Azoles are an important class of synthetic molecules widely used
in the treatment of human fungal infections and crop protection
in agriculture. They are transported ligands of both the fungal PDR
subfamily members, as well as the mammalian ABC proteins, such
as the P-glycoprotein [54,55], although differences in selectivity exist
among these transporters. The analysis of azole interactions with the
isolatedmutants revealed a strong and selective reduction of resistance
to itraconazole, associated with the C363R substitution in the H-loop of
NBD1. A gradual decrease of itraconazole resistance upon increasing
size and polarity of the residue occupying position 521 in TM1 was
also observed with the G521S and D mutants (Table 1). In contrast
these mutations showed no (C363R, G521S) or only slight decrease
(G521D) of resistance to the structurally related, but smaller in size
ketoconazole, which is a good substrate of both Cdr1p and Snq2p [34].
The G521D mutation was also associated with the reduced level of
resistance to other azoles, such as fenbuconazole (Table 1). In contrast
resistance of the G521S and D mutants to ﬂuconazole was slightly ele-
vated as compared to thewild type Cdr1p (Table 1). These data indicate
the strong and selective inﬂuence of the identiﬁed NBD and TMD resi-
dues on azole transport speciﬁcity.
Whereas the combined double mutations had only a small effect
on resistance to ﬂuconazole and ketoconazole, the strong synergistic
decrease of resistance to fenbuconazole by the double C363R-G521S,
C363R-V885G, A1208V-G521S and A1208V-V885G mutants was ob-
served (Table 1). A similar synergy was observed with itraconazole.
The strongest effect was observed with the quadruple mutant C363R,
G521S, V885G, A1208V, which showed a markedly reduced activity to-
wards the four azoles as compared to the single mutants and the wild
type Cdr1p. This underscores the importance of the interactions be-
tween the identiﬁed residues for drug translocation, and together with
the synergistic effects observed on resazurine, resoruﬁne, 4-NQO and
selected azoles, indicates their functional coupling.
3.5. Coevolutionary analysis of the residue interactions in the PDR
subfamily of ABC transporters
Recent evidence suggests that conformational changes in proteins
depend on proper long distance communication between remote
amino acids through evolutionarily conserved contacts established
in the form of a sparse network of selected intermediary residues
[40,42]. To get more insight into the interaction network in Cdr1p, and
the function of the newly identiﬁed residues, we used new methods
that allow predicting the degree of thermodynamic coupling between
protein residues, which have successfully been applied to map the
interactions in several protein families and veriﬁed by mutagenesis
[40,42,56]. These are based on the fact that substitutions of the function-
ally important residues showing some degree of conservation are oftenTable 1
The differential inﬂuence of Cdr1 wild type, single and multiple mutants on resistance to a
Cdr1
wt
C363R G521S G521D V885G A1208V
Fluconazole 549 549 1098 1098 1098 1098
Fenbuconazole >366 >366 >366 11.4 >366 >366
Ketoconazole 1.4 1.4 1.4 0.714 5.7 5.7
Itraconazole >46 2.9 11.4 0.357 >46 >46
a The minimal inhibitory concentrations MIC [μM] are indicated. The increased effect of
italics. The MIC values for the expression host bearing the triple deletion of the major mu
are shown for reference.compensated by changes at other positions. As a consequence of such
coevolutionary events, the distribution of amino acids occupying a
given position in the largeMSA changes in the subalignment containing
a speciﬁc substitution (perturbation) at another site [42]. The magni-
tude of this change, reﬂecting the energetic coupling of residue pairs
can be calculated and presented in the form of a color-coded two di-
mensional matrix, which for the PDR subfamily is presented in Fig. 6A.
This reveals the pseudosymmetrical pattern of interactions, reﬂecting,
the two fold rotational symmetry typically observed in structures of
ABC transporters, including the three dimensional, low resolution re-
construction of Pdr5p [17] and important sequence differences between
the duplicated subunits [7,8]. Functionally linked residues, should be
characterized by a similar proﬁle of energetic coupling to other residues
in the protein. The identiﬁcation of such groups has been performed by
the subsequent two dimensional clustering analysis of the interaction
matrix (Fig. 6B). This led to the identiﬁcation of V885 as a member of
a larger cluster of residues (Fig. 6C) showing self consistency, char-
acterized by a similar pattern of residue coupling to all substitutions
(perturbations), and substitutions (perturbations) showing a similar
pattern of coupling to all residues. This characteristic feature of related,
network-forming residues was previously seen by others [40,42,56].
Interestingly several residues revealed by the two dimensional
clustering to be coevolutionarily related to V885 are located in the
region of the conserved X-loop [53], that is part of the communica-
tion pathway between the NBD and TM domains that shows high
mobility in molecular dynamics simulations of ABC exporters [57,58].
These residues include G998 located in the X-loop and A990, which to-
gether with G1000 surround this conserved motif from both sides.
G1000 immediately precedes the degenerate motif C of NBD2, which
is followed by R1006 also belonging to the V885 cluster. Interestingly
K483 of Sav1866 corresponding to R1006 of Cdr1p, based on the struc-
ture based alignment, has been implicated to be involved in the forma-
tion of one of the switches mediating the interdomain communication,
in the Sav1866 homodimer [59]. Structure based alignment analysis re-
vealed another residue V952 from the V885 cluster to be located in the
proximity of the X-loop region, as a close contact between residues cor-
responding to A990 and V952 of Cdr1p in the structure based align-
ment, was observed in the crystal structures of several NBD domains.
Among other functionally important regions of ABC transporters
highlighted by the evolutionary coupling to V885 were also the A loop
of NBD2 (consensus ATP composite site 2), which based on the struc-
ture assisted alignment is in close contactwith the residues correspond-
ing to I169 and L170, aswell as the region of a loop joining alpha helices
3 and 4 of the signaling subdomain of NBD2, in which residues corre-
sponding to the identiﬁed A255, P261, Y273 of Cdr1p are located. In ad-
dition several residues located within the predicted loops joining the
transmembrane helices were also found in the V885 cluster. Structural
analysis of other ABC transporters combined with molecular dynamics
simulations suggests that these regions undergo excessive rearrange-
ments and show high mobility during the catalytic cycle [57,58,60,61].
In view of these observations it is also interesting to note the co-
evolutionary link of the V885 cluster with the central region of TM7












549 274 1098 549 34 17 4.3
23 11.4 46 92 2.9 92 0.179
1.4 0.714 2.9 2.9 0.179 0.714 0.022
1.43 0.179 5.7 11.4 0.045 0.089 0.022
combined mutations is marked in boldface. A strong synergistic increase is marked in
ltidrug transporter genes PDR5, SNQ2 and YOR1 and the Snq2p overproducing strain
Fig. 6. Analysis of statistical coupling in the PDR subfamily of ABC transporters. A) A color
coded-matrix of coupling energy values for the 2551 substitution (perturbation) analyses
on the MSA as indicated in the text (values increasing from blue, through green and yel-
low to red). Each row represents coupling energy values for subsequent residues in the
alignment (their location in the MSA is indicated by domain symbols on top) in response
to a substitution (perturbation) at another position ofMSAwhose location is indicated by
domain symbols on the left side. Each column represents coupling energies for one resi-
due over all substitutions (perturbations). B) The coupling energy matrix after two di-
mensional clustering, grouping residues showing a similar pattern of coupling energies
in response to all substitutions (perturbations) and substitutions (perturbations) showing
a similar pattern of coupling to all residues. C) Detailed view of the self consistent cluster
of residues identiﬁed by two dimensional clustering, coupled to V885 (numbers on top in-
dicate position of the amino acid residue in the Cdr1p sequence). These show a similar
pattern of coupling energies in response to substitutions at positions indicated on the
right. The indicated substitutions show also a similar pattern of coupling to the residues
indicated on top.
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drug and nucleotide binding sites
ATP hydrolysis is tightly coupled to substrate translocation in the
majority of transport systems including representatives of the ABC su-
perfamily, such as HisP [62]. The polyspeciﬁc multidrug transporters
such as P-glycoprotein are distinct in that respect and show a high
level of basal ATPase activity even in the absence of transported drugs.
Substrate binding in the TM region of P-glycoprotein is communicated
to the NBD domains, which results in the strong stimulation of ATPase
activity at low drug concentrations, whereas higher exert an inhibitory
effect [63,64].
To verify whether the identiﬁed residues interfere with signals
elicited by transported drugs, their effect on Cdr1p ATPase activity was
analyzed. In agreement with the previous observations on Pdr5p
[65–67], the inhibition of Cdr1p by high concentrations of transported
substrates was also observed with only a minor or no stimulation at
low doses for most compounds (data not shown). The response to
fenbuconazole presented in Fig. 7 is interesting as this azole antifungal
showed a signiﬁcant stimulation of the wt Cdr1p ATPase activity,
which was markedly enhanced by G521S and G521D mutations in the
TM helix 1. In contrast mutations at other three positions had an oppo-
site effect and markedly diminished the stimulation and enhanced inhi-
bition. Interestingly the single C363R substitution was sufﬁcient for
almost complete elimination of the substrate drug stimulatory effect
on ATPase activity both in the wild type context as well as in the pres-
ence of the enhancing G521S substitution, indicating interference with
a common path of signal transmission. The effect of single A1208V
and V885G mutations was of lower magnitude, however when com-
bined these two substitutions exerted an effect similar to that of a single
C363R change. An even stronger inhibitory effect was observed when
C363R and V885G mutations were combined, and with the quadrupleFig. 7. Transported drug-dependent ATPase activity of Cdr1p wild type and mutants in the
isolated plasma membranes. Membranes were isolated as described in Materials and
methods. ATPase activity was measured at 30 °C, pH 7.5 in the presence of 8 mM Mg-ATP
and 12.5 mM azide, as described in Materials and methods.
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fenbuconazole. These observations extend and further support the
long range interactions of the identiﬁed residues, observed in growth
assays, indicating a coordinated modiﬁcation of drug elicited signaling
to the NBDs.
Whereas the quadruple mutant with markedly decreased capability
to confer resistance to all tested substrates was able to hydrolyze ATP
at a rate comparable to the wild type Cdr1p at high, saturating con-
centration of 8 mM, the analysis revealed a reduced rate at lower con-
centrations associated with a ﬁvefold increase in the KM. This could
potentially contribute to decreased drug resistance observed in growth
assays as the in vivo ATP concentrations are typically in the milimolar
range [68,69]. To measure the drug transport activity of this mutant at
saturating drug and ATP concentrations, difﬁcult to control in vivo, a
new ﬂuorescence-based assay of DiOC6 transport in isolated plasma
membranes was developed. This lipophilic probe, which is also a
transported substrate of Pdr5p and P-glycoprotein, shows enhanced
ﬂuorescence upon lipid binding [70,71]. Addition of ATP to Cdr1p
overproducing plasma membrane preparation, in the presence of the
dye, was followed by a rapid decrease of ﬂuorescence intensity, which
was not observed with the control membranes not containing Cdr1p
and in the absence of ATP (Fig. 8). In line with the strong inhibition of
Cdr1p ATPase activity by oligomycin and vanadate, they also inhibited
Cdr1pmediated decrease of DiOC6 ﬂuorescence intensity, when applied
before starting the reaction with Mg-ATP. When the inhibitors were
added after the reaction has reached a steady state, a rapid restoration
of ﬂuorescence was observed. This excludes the possibility that the de-
crease of ﬂuorescence intensity resulted from degradation or chemicalFig. 8. DiOC6 transport (A) and ATP hydrolysis (B) by the wild type and mutant Cdr1p in
isolated plasma membranes. Membranes were isolated as described in Materials and
methods. Drug transport andATPase activitiesweremeasured at 30 °C, pH7.5 in the pres-
ence of either 0.8 mMor 8 mM Mg-ATP and 12.5 mMazide, as described inMaterials and
methods.modiﬁcation of the dye. The results are in line with our previous obser-
vations that Cdr1p removes drugs directly from the plasma membrane
to the externalmedium [34]. At lowATP concentrations bothATPase ac-
tivity and DiOC6 transport of the quadruple mutant were compromised
as compared to the wild type. Although the increase of ATP concentra-
tion restored the full ATPase activity also observed in the wild type, the
transport of DiOC6 showed no increase and was barely detectable. This
further supports the results from growth inhibition assays, and SCA
analysis demonstrating that ATP hydrolysis is not efﬁciently coupled
to substrate translocation in this mutant.
4. Discussion
The pathways of intramolecular communication between the two
nucleotide binding and transmembrane domains, arranged around a
two-fold symmetry axis in the tertiary structures of ABC transporters,
and their effect on substrate speciﬁcity are poorly understood.
To address this issue we combined the extensive knowledge of
the multidrug detoxiﬁcation system of the yeast S. cerevisiae with
the ease of genetic manipulation in this model organism. We took a
new approach and directed the evolution of one transporters speciﬁc-
ity towards that of the other, exploiting the previously identiﬁed dif-
ferences in the drug resistance proﬁles of the major MDR transporters
Pdr5p and Snq2p of S. cerevisiae and Cdr1p of the pathogenic yeast
C. albicans, members of the PDR subfamily of ABC transporters.
These proteins that evolved to handle a vast array of structurally
unrelated molecules are a good model for the analysis of mechanisms
of substrate translocation by MDR ABC transporters, as they share
high sequence identity, which approaches 56% between Pdr5p and
Cdr1p, 42% between Cdr1p and Snq2p and 37% between Pdr5p and
Snq2p [72–75]. This is reﬂected by the corresponding degree of over-
lap in the substrate speciﬁcity proﬁles. These are in stark contrast to
the majority of other transporters and enzymes, which usually show
a narrow speciﬁcity for individual or closely related molecules. Studies
in these systems pointed out to the importance of long distance amino
acid interactions for substrate selection. In serine proteases, such as
trypsin and chymotrypsin the speciﬁcity of catalysis has been shown
to depend on the interaction with distal surface loops that affect the
conformation of amino acids forming direct contactswith the substrates
[28,29]. These interactions have been shown to be mediated by sparse
networks of intermediary residues that are not evident even from the
3D structures, and are important for allosteric communication [42,76].
We hypothesized that the directed evolution approach targeted at
substrate proﬁle alteration could therefore point out new residues
important for intramolecular communication in the PDR subfamily of
ABC transporters.
In support of this hypothesis, our screen based on positive selec-
tion of Cdr1p mutants conferring increased resistance to Snq2p sub-
strate resazurine, identiﬁed mutations speciﬁcally clustered in each
domain of the protein. The two pairs of mutations were roughly
pseudosymmetrically located (Fig. 1) in relation to the two fold rota-
tional symmetry axis typically observed in three dimensional recon-
structions of ABC MDR transporters, including the low resolution
Pdr5p structure [17,53,61,77,78]. We believe that this characteristic
and functionally important pattern of mutations was revealed thanks
to the gain of function selection procedure and saturation of the
screen suggested by hitting the same sites in multiple independent
clones. The positive selection allowed to intrinsically eliminate the
nonfunctional, poorly expressed or incorrectly processed mutants,
contributing to much higher heterogeneity observed previously in a
few other global screens [35,79] employing negative selection for
loss of resistance. Interestingly symmetric interfaces are common to
form two-state conformational switches, and mutations affecting
allosteric communication in several ligand-gated channels [80–82]
were often found located close to the symmetry axes, which is in line
with the proposed mechanisms of allosteric signal transduction [83].
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identiﬁed residues in interdomain communication, its link with sub-
strate speciﬁcity and reveal conserved features within different sub-
families of ABC transporters.
Our mutants signiﬁcantly differ from those point mutants, previ-
ously identiﬁed within the PDR subfamily, with defects in ATP hydro-
lysis or binding as all of them reported so far conferred a decreased
level of resistance to the tested drug substrates. In particular none
of the mutants of this type has been shown to mediate increased drug
resistance or transport. In contrast our novel class of mutants showed
selective alterations in speciﬁcity including increased capability to
transport some of Snq2p substrates. These include the resoruﬁn deriva-
tives, as revealed by the newly developed assay of resoruﬁn acetate
transport. A parallel drastic reduction of resistance was observed for se-
lected azoles, such as itraconazole in the C363R and G521S/D mutants,
the effect increasing with the size and polarity of residue 521, the latter
being also more sensitive to fenbuconazole. Only minor changes in
resistance to some compounds such as cycloheximide or ﬂuconazole,
selective for Pdr5p and Cdr1p, were seen.
The stable high level overproduction achieved for the heterologous
MDR transporter Cdr1p in a strain devoid of the major endogenous
efﬂux pumps PDR5, SNQ2 and YOR1, reduced the background of endog-
enous activities and increased the accuracy of the functional character-
ization ofmutants. Thesewere overproduced at the level comparable to
the wild type protein as determined by two independent approaches,
and located correctly to the plasma membrane, demonstrating that
the large differences in drug resistance and transport result from the
functional alterations of the proteins, rather than from differences in
the expression level or mislocalization.
Given the lack of Cdr1p structural information, to gain insight into
the relative location of themutations, their positions have beenmapped
onto the available three dimensional structures of ABC transporters
NBDs using structure based alignment. This approach was validated
by the relatively high sequence conservation of these cytosolic regions
and the fact that the tertiary structures are generally much better con-
served than the corresponding sequences. Analysis of the available
structures of completeMDR transporters indicated that themutated re-
gions in both NBDs as well as in central parts of TM helix 1 and 7 are far
apart. Thus the strong synergistic effects on drug transport and resis-
tance as well as the drug dependent ATPase activity revealed by double
mutant analysis, must result from long distance allosteric interactions
between the identiﬁed residues. Their role in interdomain communica-
tion was also suggested by SCA, supported by analysis of available mu-
tational data in multiple subfamilies of ABC transporters. The observed
pseudosymmetry of the intramolecular interaction network in Cdr1p
reﬂected the pseudosymmetrical location of the newly identiﬁedmuta-
tions and the observations of others [18,59,33]. V885 was identiﬁed asFig. 9. Mapping the position of V885 of Cdr1p onto the structure of mouse P-gp (3G60) (A)
residues V1056 of P-gp and A29 of HisP, respectively with the strand preceding the H-looppart of the larger cluster of interacting residues (Fig. 6C), that included
the TMhelix 7 residue L1209, being in direct contact with the preceding
A1208 identiﬁed in our screen. It is likely that the selection conditions
for increased resazurine resistance required a change in this neighbor-
ing residue to allow for more subtle changes in drug speciﬁcity. A
reminiscent situation has been observed with disease causing muta-
tions in several human proteins, which omitted the critical for function
coevolving residues, and located in their immediate surrounding mod-
ulating their function through direct contacts [84]. Another possibility
may be related to the inherent sensitivity of coevolution detecting algo-
rithms to the conservation level of amino acids in each column of the
multiple sequence alignment [85]. Additional limits are imposed by
the clustering algorithms which allow the allocation of a given residue
to only one cluster. Given the large size of ABC transporters and the
complexity of the coordinated interdomain interactions, required for
completion of the transport cycle energized by ATP hydrolysis, it is
likely that the interaction network sampled by the SCA approach is
underrepresented.
Nevertheless the high predictive power of SCA has previously been
documented experimentally in several protein families of smaller size
[42,56]. The validity of our approach is further supported by the fact
that many residues evolutionarily related to V885 (Fig. 6C) located
within or in close contact with the highly mobile regions, previously
shown by molecular dynamics simulations to undergo extensive
rearrangements during the catalytic cycle of ABC transporters. This is
in linewith the observations of others that the coevolving residues clus-
ter in ﬂexible regions of proteins involved in allosteric communication
[86–88]. These regions include the X-loop, A-loop, the loop between
alpha helices 3 and 4 of the signaling subdomain of NBD2 and loops
connecting the transmembrane helices [53,57–61]. In addition the
SCA analysis of Cdr1pwas in agreementwith the availablemutagenesis
data not only on members of the PDR subfamily, including the recent
reports on intramolecular communication in Pdr5p [32,33], but also
with numerous data from other groups of ABC transporters, including
P-glycoprotein. Interestingly the X-loop region, predicted to commu-
nicate with the Walker A preceding V885 in Cdr1p, has previously
been shown to be involved in the control of substrate speciﬁcity of the
mouse Mdr3 [89], supporting its role in signal transmission to the
TMDs. Several other observations point out to the important and evolu-
tionarily conserved role for theWalker A preceding region, correspond-
ing to V885 of Cdr1p in communication between the NBD and TMD
domains in multiple ABC transporter subfamilies, including exporters
of inverted topologies, importers and the CFTR Cl− channel.
Interestingly residues corresponding to V885 of Cdr1p, mapping at
the end of strand 2 of the catalytic subdomain of NBD2 make con-
served contact with the region preceding the H-loop in the structures
of several NBDs of ABC transporters. This is shown in Fig. 9 for the, and HisP (1B0U) (B), reveals a conservation of the close contact of the corresponding
(residues T1222 of P-gp, and T205 of HisP).
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A29 and T205). A similar contact was observed between the symmet-
rically located, corresponding residues V413 and T577 in the opposite
NBD1 of the mouse mdr3 P-gp.
Recent molecular dynamics simulations revealed this region as an
anchor and pivot for the preceding helix D of the helical subdomain
[90]. Movements of helix D occurred in concert with residues located
in the D-loop on its opposite side aswell asmotive C, which follows im-
mediately the X loop. The region preceding the H-loop has previously
been shown to communicate with, and affect the function of the trans-
membrane domains in both HisP and P-gp. Substitution T205M of His P
enabled the uptake of histidine in the absence of the otherwise in-
dispensable substrate binding protein HisJ [91], whereas T205A sup-
pressed the effect of the HisJ mutation which inactivated its domain
responsible for interactionwith the transmembrane region of the trans-
porter. Alteration of the drug resistance proﬁle was a consequence of
the T578C mutation in the mouse mdr3 P-glycoprotein [89]. This resi-
due remaining in close contact with T577 and separated by four amino
acids from the conserved His of the H-loop in NBD1, is located symmet-
rically to the corresponding C1223 of NBD2 and in the alignment follows
T205 of HisP. Finally this region in the NBD1 of yeast Pdr5p (T363 corre-
sponding to I579 of themousemdr3 P-glycoprotein) has been recovered
as a partial suppressor of L183P (which corresponds to V413 of P-gp,
A29 of HisP, and M177 of Cdr1p- in the location corresponding to
V885 but in the opposite NBD1 domain)which resulted in the endoplas-
mic reticulum retention of the protein [92]. These contacts are of partic-
ular interest, in light of the recent observation that a mutation H1068A
of the conserved histidine, deﬁning theH-loop of Pdr5pNBD2, selective-
ly affected substrate speciﬁcity [73]. This was also the case for the iden-
tiﬁed C363R substitution in the pseudosymmetrically located region of
the opposite NBD1 of Cdr1p that appeared functionally coupled to
V885 in the double mutant analysis. These observations further conﬁrm
the conserved nature of the inﬂuence of theWalker A preceding region
andV885 of Cdr1p and its corresponding residues on the status of trans-
membrane domains in a diverse range of ABC transporters, pointing out
to the importance of the H-loop region in this process. Of note is also the
fact that theH-loop and X loop regions have been revealed as important,
disease associated structural hotspots in human ABC transporters [93].
The S1235R substitution in CFTR, a unique member of the ABC su-
perfamily serving as a chloride channel which when malfunctions is
associated with mucoviscidosis may lead to symptoms of varying de-
grees when heterozygous with other more severe mutations. This lo-
cation corresponding to K886 of Cdr1p, a residue next to and in direct
contact with V885 identiﬁed in our mutagenesis screen, affected the
functional properties of the transmembrane domains, increasing the
open probability of the chloride channel [94].
Given the effect observed in CFTR it is likely that the altered resis-
tance proﬁle of the V885G and the identiﬁed functionally related substi-
tutions could result from changes in the dynamics or range of motions
of the transmembrane helices, which would be in line with the model
of kinetic substrate selection proposed by Ernst et al. [67]. It assumes
that modiﬁcations of drug speciﬁcity may result from changes in the
equilibration time of transported substrates with the drug binding site
which depend on the kinetics of conformational changes. Interestingly
an altered kinetics of CFTR channel was also a result of mutations in res-
idues predicted to directly interact with the adenine ring of ATP and the
central part of TM helix 6 [95,96]. Thus the large increase of the KM for
ATP hydrolysis of the quadruple C363R, G521S, V885G, A1208V Cdr1p
mutant is likely to be associated with the altered kinetics of transport
related conformational changes resulting in profound changes in the
drug resistance proﬁle and markedly reduced resistance and transport
mediated by this allele. This would be consistentwith the drug andmu-
tation selective effects on ATPase activity and the marked hypersensi-
tivity of the quadruple mutant to fenbuconazole inhibition, indicating
maintenance of some sort of interdomain communication even in this
transport compromised mutant.In linewith this, the increasing polarity of residues in the TMhelices,
which is the case of the identiﬁed G521S and D substitutions, has been
shown previously to promote formation of interhelical hydrogen bonds
in CFTR and P-glycoprotein and alter, as a consequence, the alignment
and movements of the TM helices associated with modiﬁcation of
substrate speciﬁcity [97,98]. As glycine and alanine residues have an im-
portant role inmediating TMhelix interactions and occur at an increased
frequency at helix crossing points [99,100], a similar consequence may
result from the substitution of A1208 by the more bulky V. Of note is a
role of the G185V mutation in TM helix 3 of human P-glycoprotein,
suggested as a pivotal point in the communication between drug and
nucleotide binding domains and resulting in a more efﬁcient transport
of colchicine [64].
Altogether mutational data in multiple subfamilies of ABC trans-
porters combined with the functional and SCA analysis of the newly
identiﬁed Cdr1p residues suggest their important and conserved role
in communication between the NB and TM domains.
Our results contribute towards better understanding of the intramo-
lecular communication within ABC superfamily proteins, which is of
vital importance for the understanding of their mechanism of action
and substrate selectivity, as well as for a better control of multidrug re-
sistance phenomena in the clinical setting.
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